BI 1358894 is an investigational antidepressant that works as a transient receptor potential cation channel inhibitor. It is developed by Boehringer Ingelheim. As of 2025, it is in Phase II clinical trials for the treatment of borderline personality disorder.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.